Update in Prolactinomas

Jae Won Hong; Eun Jig Lee

doi:10.7599/hmr.2012.32.4.192

Journal List > Hanyang Med Rev > v.32(4) > 1044125

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Hong and Lee: Update in Prolactinomas

Review Article

Hanyang Medical Reviews

Hanyang Medical Reviews 2012; 32(4): 192-196.

Published online: 28 November 2012

DOI: https://doi.org/10.7599/hmr.2012.32.4.192

Update in Prolactinomas

Jae Won Hong, Eun Jig Lee

Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author: Eun Jig Lee. Division of Endocrinology, Department of Internal Medicine, Yonsei Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: +82-2-2228-5003, Fax: +82-2-364-3636, ejlee423@yuhs.ac

Received 8 August 2012 Revised 12 October 2012 Accepted 19 October 2012

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Prolactinomas are frequent causes of gonadal dysfunction and infertility. Dopamine agonists are the main treatment of prolactinoma and the excellent efficacy of the dopamine agonist is well known. Current challenges related to the treatment of prolactinomas include the relationship of long term use of cabergoline and cardiac valvulopathy, the remission after discontinuation of dopamine agonists, the management of pregnant women with prolactinoma, and the role for surgery on long-term management of prolactioma. Herein, these current issues and questions in the management of prolactinomas, including safety of cabergoline, recurrence after discontinuance of dopamine agonist, pregnancy, and role of surgical resection are addressed.

Keywords: Prolactinoma, Dopamine Agonists, Ergolines, Heart Valve Diseases

References

1. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010. 72:377–382.

2. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997. 82:2102–2107.

3. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006. 27:485–534.

4. Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010. 362:1219–1226.

5. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007. 356:29–38.

6. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007. 356:39–46.

7. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009. 23:575–596.

8. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008. 62:1864–1869.

9. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008. 93:3777–3784.

10. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009. 70:104–108.

11. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008. 93:3348–3356.

12. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008. 159:1–5.

13. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010. 72:53–58.

14. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009. 12:153–157.

15. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008. 159:R11–R14.

16. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008. 31:1119–1123.

17. Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012. 15:44–49.

18. Kars M, Dekkers OM, Pereira AM, Romijn JA. Update in prolactinomas. Neth J Med. 2010. 68:104–112.

19. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003. 349:2023–2033.

20. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009. 94:2428–2436.

21. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010. 95:43–51.

22. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf). 2005. 63:26–31.

23. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med. 1985. 312:1364–1370.

24. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf). 2008. 68:66–71.

25. Motivala S, Gologorsky Y, Kostandinov J, Post KD. Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am. 2011. 40:827–836.

26. Christin-Maitre S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris). 2007. 68:106–112.

27. Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clin Proc. 1983. 58:108–121.

28. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983. 309:280–283.

29. Schlechte JA, Sherman BM, Chapler FK, VanGilder J. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab. 1986. 62:1296–1301.

30. Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. J Neurooncol. 2001. 54:139–150.

31. Fahlbusch R, Buchfelder M, Schrell U. Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J Neurosurg. 1987. 67:807–815.

32. Couldwell WT, Weiss MH. Medical and surgical management of microprolactinoma. Pituitary. 2004. 7:31–32.

33. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008. 158:11–18.

TOOLS

Similar articles